Tectonic Therapeutic, Inc. TECX R2K
Healthcare · Biotechnology · United States
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
READ MORE ›$31.17
+44.91% 1Y
Market & Price
Market Cap
$588.06M
Current Price
$31.17
High / Low (52W)
$35.87 / $14.71
Beta
-
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$13.41
Price to Book
2.32
P/S
-
EV/EBITDA
-3.88
Dividend Yield
-
Profitability & Returns
ROCE
-28.98%
ROE
-31.42%
ROA
-20.72%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-1.34
EPS (TTM)
$-4.46
Balance Sheet & Liquidity
Debt/Equity
2.01
Quick Ratio
18.28
Current Ratio
18.51
Debt
$4.63M
Total Assets
$261.04M
Current Assets
$257.36M
Working Capital
$247.69M
Ownership
Promoter Holding
39.34%
Chg in Prom Hold
-
FII / Inst Holding
74.13%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$355.80M
Total Revenue (TTM)
-
EBITDA
$-91.72M
Free Cash Flow
$-44.70M
Operating Cash Flow
$-65.41M
Shares Outstanding
18.87M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-43.48%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -43.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TECX Tectonic Therapeutic, Inc. R2K | 31.17 | - | $588.06M | - | -28.98% | -31.42% | - | -43.48% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.30M | 22.33M | 21.89M | 21.52M | 27.30M |
| Operating Income | -2.54M | -6.37M | -7.79M | -9.55M | -12.23M | -17.70M | -16.61M | -18.06M | -26.59M | -28.86M | -36.72M | -26.88M | -31.38M | -32.62M | -29.42M | -27.77M | -22.98M | -25.22M | -10.63M | -10.11M | -12.97M | -11.42M | -19.64M | - | -18.30M | -22.33M | -21.89M | -21.52M | -27.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.53M | -18.65M | -18.68M | -18.63M | -24.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00K | 17.00K | 14.00K | 12.00K | 8.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.91M | -19.01M | -19.04M | -18.97M | -25.24M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 976.00K | 0 | 254.00K | - |
| Net Income | -2.53M | -6.44M | -8.24M | -10.51M | -11.59M | -17.10M | -16.05M | -17.14M | -25.97M | -28.83M | -36.78M | -26.90M | -31.39M | -32.61M | -29.83M | -28.05M | -22.97M | -14.45M | -10.46M | -10.05M | -15.22M | -12.67M | -17.72M | - | -15.91M | -19.98M | -19.04M | -19.23M | -25.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.74 | -0.75 | -0.68 | -0.64 | -0.52 | -0.57 | -8.51 | -7.62 | -10.97 | -4.34 | -1.20 | - | -0.93 | -1.07 | -1.02 | -1.03 | -1.34 |
| R&D Expense | 1.88M | 5.41M | 5.65M | 7.41M | 9.23M | 12.45M | 12.27M | 13.04M | 18.27M | 20.87M | 28.51M | 18.53M | 22.54M | 23.04M | 19.25M | 18.88M | 15.92M | 17.33M | 8.77M | 8.13M | 10.82M | 7.07M | 14.32M | - | 13.04M | 17.18M | 16.93M | - | 20.87M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 32.83M | 44.65M | 58.02M | 84.04M |
| Operating Income | -18.39M | -46.24M | -75.81M | -120.23M | - | -32.83M | -44.65M | -58.02M | -84.04M |
| EBITDA | - | - | - | - | - | -31.03M | -41.19M | -56.23M | -71.48M |
| Interest Expense | - | - | - | - | - | 144.00K | 152.00K | 107.00K | 63.00K |
| Pretax Income | - | - | - | - | - | -32.18M | -42.82M | -57.98M | -72.92M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 1.23M |
| Net Income | -18.65M | -46.36M | -72.97M | -119.71M | - | -32.18M | -42.82M | -57.98M | -74.15M |
| Diluted EPS | - | - | - | - | -0.61 | -2.18 | -2.91 | -6.83 | - |
| R&D Expense | 15.19M | 35.09M | 54.97M | 87.24M | 83.11M | 72.19M | 36.97M | 41.36M | 63.49M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -43.48% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +44.91% |
| 6 Months: | +46.68% |
| 3 Months: | +32.92% |
| 1 Month: | +15.15% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.02M | 133.48M | 200.51M | 271.23M | - | 47.21M | 39.40M | 152.91M | 261.04M |
| Current Assets | - | - | - | - | - | - | 37.04M | 30.88M | 146.86M | 257.36M |
| Cash & Equivalents | - | 5.96M | 126.30M | 187.04M | 259.68M | - | 35.97M | 28.77M | 141.24M | 253.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 3.66M | 11.29M | 14.50M | 16.89M | - | 92.86M | 124.03M | 12.13M | 9.71M |
| Current Liabilities | - | 2.62M | 10.61M | 14.02M | 16.61M | - | 7.84M | 40.89M | 11.61M | 9.67M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 5.79M | 4.34M | 3.30M | 1.28M |
| Total Equity | -4.58M | -23.14M | 122.18M | 186.01M | 254.34M | - | -45.65M | -84.64M | 140.78M | 251.33M |
| Shares Outstanding | - | - | - | - | - | - | 14.73M | 14.73M | 14.86M | 18.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.38M | -37.65M | -67.67M | -98.80M | - | -27.64M | -40.68M | -59.08M | -60.08M |
| Investing Cash Flow | -383.00K | -1.83M | -1.58M | -1.18M | - | -2.09M | -279.00K | -156.00K | -138.00K |
| Financing Cash Flow | 17.37M | 160.29M | 129.99M | 172.62M | - | 37.63M | 33.75M | 171.71M | 173.35M |
| Capital Expenditure | -383.00K | -1.83M | -1.58M | -1.18M | - | -2.09M | -279.00K | -156.00K | -208.00K |
| Free Cash Flow | -16.77M | -39.48M | -69.25M | -99.98M | - | -29.73M | -40.96M | -59.24M | -60.29M |
| Net Change in Cash | - | - | - | - | - | 7.90M | -7.21M | 112.48M | 113.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| ROE % | 80.6% | -37.9% | -39.2% | -47.1% | - | 70.5% | 50.6% | -41.2% | -29.5% |
| ROCE % | -418.1% | -37.6% | -40.6% | -47.2% | - | -83.4% | 2,998.5% | -41.1% | -33.4% |
Shareholding Pattern
Insiders
39.34%
Institutions
74.13%
Public Float
122.21%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 2.82M | $87.78M |
| 2 | TCG Crossover Management, LLC | 6.39% | 1.20M | $37.55M |
| 3 | Aberdeen Group plc | 6.05% | 1.14M | $35.58M |
| 4 | Blackrock Inc. | 4.56% | 860.35K | $26.81M |
| 5 | Braidwell LP | 4.49% | 847.15K | $26.40M |
| 6 | First Light Asset Management, LLC | 3.43% | 647.74K | $20.19M |
| 7 | Baker Bros. Advisors, LP | 3.22% | 607.79K | $18.94M |
| 8 | 5AM Venture Management, LLC | 3.22% | 606.66K | $18.91M |
| 9 | Vanguard Capital Management LLC | 2.51% | 473.53K | $14.76M |
| 10 | Vestal Point Capital, LP | 1.74% | 328.00K | $10.22M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TECX
No recent headlines available.